Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured 62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs has again received project funding from the Innovative Medicine’s Initiative.
Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgènes armed oncolytic immunotherapies.
Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
In its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.